TC Biopharm (Holdings) Plc (TCBPY)

TC Biopharm (Holdings) Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1.22	2.46	4.81	1.57	0.75
Cash & Short-Term Investments	1.22	2.46	4.81	1.57	0.75
Cash Growth	-50.64%	-48.78%	206.89%	109.45%	-21.80%
Other Receivables	0.66	1.1	1.78	1.41	1.18
Receivables	0.66	1.1	1.78	1.41	1.18
Prepaid Expenses	0.79	0.83	0.84	0.81	0.23
Other Current Assets	3.11	1.31	0.03	0.07	0.05
Total Current Assets	5.77	5.7	7.45	3.86	2.22
Property, Plant & Equipment	2.09	2.62	3.29	3.68	4.63
Other Intangible Assets	0.47	0.62	0.55	0.48	0.42
Total Assets	8.33	8.93	11.29	8.02	7.27
Accounts Payable	1.39	1.85	0.88	1.42	0.64
Accrued Expenses	2.19	2.41	0.94	2.33	0.92
Short-Term Debt	-	-	0.65	13.73	-
Current Portion of Leases	0.33	0.31	0.33	0.77	0.44
Current Income Taxes Payable	0.24	0.14	0.29	0.31	0.14
Current Unearned Revenue	-	-	-	1.98	1.98
Other Current Liabilities	0	0.05	6.06	0.04	0.06
Total Current Liabilities	4.15	4.75	9.16	20.58	4.19
Long-Term Leases	1.17	1.5	1.8	2.14	2.58
Long-Term Unearned Revenue	-	-	-	1.87	3.84
Total Liabilities	5.32	6.25	10.96	24.58	10.61
Common Stock	0.65	0.4	0.4	0.2	0.19
Additional Paid-In Capital	54.92	42.69	33.31	-	-
Retained Earnings	-52.56	-40.4	-33.37	-33.47	-19.89
Comprehensive Income & Other	-	-	-	16.71	16.35
Shareholders' Equity	3.01	2.69	0.33	-16.56	-3.35
Total Liabilities & Equity	8.33	8.93	11.29	8.02	7.27
Total Debt	1.5	1.8	2.78	16.63	3.03
Net Cash (Debt)	-0.28	0.66	2.03	-15.07	-2.28
Net Cash Growth	-	-67.41%	-	-	-
Net Cash Per Share	-3.01	-	-	-	-
Filing Date Shares Outstanding	2.1	0.02	-	-	-
Total Common Shares Outstanding	0.64	-	-	-	-
Working Capital	1.63	0.95	-1.72	-16.72	-1.97
Book Value Per Share	4.72	-	-	-	-
Tangible Book Value	2.54	2.07	-0.22	-17.04	-3.77
Tangible Book Value Per Share	3.99	-	-	-	-
Machinery	0.49	0.45	0.43	0.42	0.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.